Byotrol plc Announces its Unaudited Interim Results for the Nine Month Period Ended 30 September 2005.

MANCHESTER, England -- Byotrol (LSE:BYOT) is an anti microbial technology company. The patented technology has already generated a range of materials that have been extensively tested and found to safely reduce or eliminate the threats caused by micro-organisms. The Company is now engaged in the process of obtaining key regulatory approvals and developing sales channels in its target markets.

HIGHLIGHTS

--Results are presented for the first nine months of the Company's operation including six months prior to the Company's flotation on AIM on 6 July 2005;

--The Company successfully raised GBP 3 million gross, GBP 2.5 million net of expenses, by way of the placing completed on 6 July 2005;

--The loss for the period of GBP 462,808 is in line with the Directors' plan for this period;

--Net cash as at 30 September 2005 was GBP 2,035,279;

--Progress has been made toward achieving EPA registration;

--A trial has commenced with a major NHS hospital and this is initially expected to run until March 2006;

--The sales and marketing team has been strengthened;

--Sales channels in key healthcare and food processing markets have been developed; and

--New customers have been acquired in specialist markets where additional regulatory approvals are not required.

Commenting on the Company's performance to date, David McRobbie, CEO of Byotrol plc, said:

"I am extremely pleased with the progress we have made since becoming a quoted company in July 2005. We have made good initial progress with sales slightly ahead of target and our costs have come in under budget. We are making important steps in our key markets of healthcare, food processing and the industrial sector and our focus has been on securing key approvals, establishing product trials in selected markets, generating long term sales opportunities and recruiting key individuals to help us meet our objectives. I am confident that much of the progress we have made in the past six months will start to deliver significant growth over the next six to twelve months in line with our business plan".

Note to editors: a full version of this announcement is available on the UK regulatory circuit.